Search - tctmd.com

Displaying 401 - 420 of 1163

Sort: Relevancy | Date

Presentation THT 2024

PADN for PH in Left Heart Disease

Presenter: Greg Lewis

March 06, 2024

Presentation THT 2024

Emerging Therapies for Residual Pulmonary Hypertension After Pulmonary Endarterectomy

Presenter: Paul Forfia

March 06, 2024

Presentation THT 2024

A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms.

Presenter: Thomas Hanff

March 06, 2024

Presentation THT 2024

Pulmonary Artery Denervation

Presenter: Alex M. K. Rothman

March 06, 2024

Presentation THT 2024

DPP3-Based Biotherapy in Cardiogenic Shock

Presenter: Mahir Karakas

March 06, 2024

Presentation THT 2024

PH-HFpEF: Levosimendan

Presenter: Sanjiv J. Shah

March 06, 2024

Presentation THT 2024

Disaggregating Left Heart Disease-Pulmonary Hypertension

Presenter: Bradley A. Maron

March 06, 2024

Presentation THT 2024

Pulsatile ECMO

Presenter: Nader Moazami

March 06, 2024

Presentation THT 2024

RV-PA Coupling and PV Loops: The Art of Hemodynamics

Presenter: Ryan J. Tedford

March 06, 2024

Presentation THT 2024

Ivabridine in Cardiogenic Shock

Presenter: Maya Guglin

March 06, 2024

Presentation THT 2024

The Conundrum of Clinical Trials in Cardiogenic Shock

Presenter: JoAnn Lindenfeld

March 06, 2024

Presentation THT 2024

Reclassification of PH Based with New Endo-Phenotypes

Presenter: Evelyn Miriam Horn

March 06, 2024

Presentation THT 2024

Impact Of Rapid Up-Titration of Guideline-Directed Medical Therapies On Quality of Life: Insights From The STRONG-HF Trial

Presenter: Kamile Cerlinskaite-Bajore

March 06, 2024

Presentation THT 2024

Post PE Syndrome

Presenter: Paul Forfia

March 06, 2024

Presentation THT 2024

Introduction Of Guideline Directed Medical Therapy And Native Heart Recovery In Patients Supported By Impella 5.5

Presenter: Kanika P. Mody

March 06, 2024

Presentation THT 2024

Contemporary Management of High-Risk PE: Focus on Temporary MCS Therapies and Surgical Thrombectomy

Presenter: Candice Lee

March 06, 2024

Presentation THT 2024

Multicenter Development and Validation of a Supervised Machine Learning Risk Model to Predict Right Ventricular Failure Following Mechanical Circulatory Support: The STOP-RVF Score

Presenter: Stavros G. Drakos

March 06, 2024

Presentation THT 2024

Case Resolution

Presenter: Sareena George

March 06, 2024

Presentation THT 2024

AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial

Presenter: Deya Alkhatib

March 06, 2024

Presentation THT 2024

Catheters Are Over-Rated! Heparin as the Primary Option

Presenter: Sanjum S. Sethi

March 06, 2024

Advertisement

PADN for PH in Left Heart Disease

Emerging Therapies for Residual Pulmonary Hypertension After Pulmonary Endarterectomy

A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms.

Pulmonary Artery Denervation

DPP3-Based Biotherapy in Cardiogenic Shock

PH-HFpEF: Levosimendan

Disaggregating Left Heart Disease-Pulmonary Hypertension

Pulsatile ECMO

RV-PA Coupling and PV Loops: The Art of Hemodynamics

Ivabridine in Cardiogenic Shock

The Conundrum of Clinical Trials in Cardiogenic Shock

Reclassification of PH Based with New Endo-Phenotypes

Impact Of Rapid Up-Titration of Guideline-Directed Medical Therapies On Quality of Life: Insights From The STRONG-HF Trial

Post PE Syndrome

Introduction Of Guideline Directed Medical Therapy And Native Heart Recovery In Patients Supported By Impella 5.5

Contemporary Management of High-Risk PE: Focus on Temporary MCS Therapies and Surgical Thrombectomy

Multicenter Development and Validation of a Supervised Machine Learning Risk Model to Predict Right Ventricular Failure Following Mechanical Circulatory Support: The STOP-RVF Score

Case Resolution

AI Assisted Identification of Super responders for Ultrafiltration can Reduce 90-Day Readmission Rates: Evidence from AVOID-HF Trial

Catheters Are Over-Rated! Heparin as the Primary Option

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content